Provider of development services to drugmakers, Ergomed (AIM: ERGO) said it will pay $12 million for the Phase III trial for drug to treat to head and neck cancer following an expanded agreement with CEL-SCI Corp (NYSE MKT: CVM).
UK-based Ergomed has increased its contribution from the initial $10 million, the companies said in a joint statement. Under the new agreement, Ergomed will pay up to $12 million towards the cost of performing clinical services for the Phase III study in exchange for milestone and royalty payments
The two companies are undertaking the Phase III trial of CEL-SCI’s trial-stage immunotherapy Multikine (leukocyte interleukin, Injection).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze